Return Of Vertex’s Ivacaftor To FDA Panel May Signal Efficacy Concerns
This article was originally published in The Pink Sheet Daily
Executive Summary
Kalydeco raced to market for cystic fibrosis, but effort to get ‘breakthrough’ approval with lumacaftor for much larger patient population may have FDA worrying about the meaningfulness of pivotal efficacy results.